Kelly is a Managing Director in the Healthcare Investment Banking Group at Wedbush PacGrow and Head of the Biopharma practice. Kelly joined Pacific Growth Equities in 2004 and has completed over 350 transactions with the firm raising over $38 billion. Prior to Wedbush, Kelly worked at ICOS (now part of Eli Lilly) on Cialis and the PDE4 program. She is a member of the Intellectual Property Committee at the Benaroya Research Institute as well as the Board of Directors for the Retinal Degeneration Fund, a not-for-profit focused on making venture philanthropy investments on behalf of the Foundation Fighting Blindness. Kelly holds an AB in Molecular Biology from Princeton University where she completed her thesis under the direction of Dr. Thomas Shenk, the Elkins Professor in the Life Sciences and former board member of Merck & Co.